6zzw
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
==Structure of the N terminal domain of Bc2L-C lectin (1-131) in complex with Globo H (H-type 3) and CAS No 912569-62-1== | ==Structure of the N terminal domain of Bc2L-C lectin (1-131) in complex with Globo H (H-type 3) and CAS No 912569-62-1== | ||
| - | <StructureSection load='6zzw' size='340' side='right'caption='[[6zzw]]' scene=''> | + | <StructureSection load='6zzw' size='340' side='right'caption='[[6zzw]], [[Resolution|resolution]] 1.90Å' scene=''> |
== Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6ZZW OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6ZZW FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[6zzw]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/Burcj Burcj]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6ZZW OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6ZZW FirstGlance]. <br> |
| - | </td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6zzw FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6zzw OCA], [https://pdbe.org/6zzw PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6zzw RCSB], [https://www.ebi.ac.uk/pdbsum/6zzw PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6zzw ProSAT]</span></td></tr> | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=QT5:[3-(2-methylimidazol-1-yl)phenyl]methanamine'>QT5</scene>, <scene name='pdbligand=FUC:ALPHA-L-FUCOSE'>FUC</scene>, <scene name='pdbligand=GAL:BETA-D-GALACTOSE'>GAL</scene>, <scene name='pdbligand=GLA:ALPHA+D-GALACTOSE'>GLA</scene>, <scene name='pdbligand=NGA:N-ACETYL-D-GALACTOSAMINE'>NGA</scene></td></tr> |
| + | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">BCAM0185 ([https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=216591 BURCJ])</td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6zzw FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6zzw OCA], [https://pdbe.org/6zzw PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6zzw RCSB], [https://www.ebi.ac.uk/pdbsum/6zzw PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6zzw ProSAT]</span></td></tr> | ||
</table> | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Burkholderia cenocepacia is an opportunistic gram-negative bacterium that causes infections in patients suffering from chronic granulomatous diseases and cystic fibrosis. It displays significant morbidity and mortality due to extreme resistance to almost all clinically useful antibiotics. The bacterial lectin BC2L-C expressed in B. cenocepacia is an interesting drug target involved in bacterial adhesion and subsequent deadly infection to the host. We solved the first high resolution crystal structure of the apo form of the lectin N-terminal domain (BC2L-C-nt) and compared it with the ones complexed with carbohydrate ligands. Virtual screening of a small fragment library identified potential hits predicted to bind in the vicinity of the fucose binding site. A series of biophysical techniques and a X-ray crystallographic screening were employed to validate the interaction of the hits with the protein domain. The X-ray structure of BC2L-C-nt complexed with one of the identified active fragments confirmed the ability of the site computationally identified to host drug-like fragments. The fragment affinity could be determined by titration microcalorimetry. These structure-based strategies further provide an opportunity to elaborate the fragments into high affinity anti-adhesive glycomimetics, as therapeutic agents against B. cenocepacia. | ||
| + | |||
| + | Prediction and Validation of a Druggable Site on Virulence Factor of Drug Resistant Burkholderia cenocepacia.,Lal K, Bermeo R, Cramer J, Vasile F, Ernst B, Bernardi A, Belvisi L, Varrot A, Imberty A Chemistry. 2021 Mar 26. doi: 10.1002/chem.202100252. PMID:33769626<ref>PMID:33769626</ref> | ||
| + | |||
| + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
| + | </div> | ||
| + | <div class="pdbe-citations 6zzw" style="background-color:#fffaf0;"></div> | ||
| + | == References == | ||
| + | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
| + | [[Category: Burcj]] | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
| - | [[Category: Bermeo R]] | + | [[Category: Bermeo, R]] |
| - | [[Category: Imberty A]] | + | [[Category: Imberty, A]] |
| - | [[Category: Lal K]] | + | [[Category: Lal, K]] |
| - | [[Category: Varrot A]] | + | [[Category: Varrot, A]] |
| + | [[Category: Anti-adhesive therapy]] | ||
| + | [[Category: Drug design]] | ||
| + | [[Category: Drug resistance]] | ||
| + | [[Category: Fragment based screening]] | ||
| + | [[Category: Glycomimetic]] | ||
| + | [[Category: Lectin]] | ||
| + | [[Category: Sugar binding protein]] | ||
Revision as of 10:44, 28 July 2021
Structure of the N terminal domain of Bc2L-C lectin (1-131) in complex with Globo H (H-type 3) and CAS No 912569-62-1
| |||||||||||
